Bui Lab Publications

  1. Bui, J.D., Carayannopoulos, L.N., Lanier, L.L., Yokoyama, W.M., and Schreiber, R.D. IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors. Journal of Immunology 176 (2):905-13, 2006.
  2. Bui, J.D., Uppaluri, R., Hsieh, C., and Schreiber, R.D. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res. 2006 Jul 15;66(14):7301-9.
  3. Bui, J.D. and Schreiber, R.D. Cancer Immunosurveillance, immunoediting, and inflammation :Independent or interdependent processes? Current Opinion in Immunology. 2007, 19(2):203-8.
  4. Yadav, D., Ngolab, J., Lim, R., Krishnamurthy, S., Bui, J.D. Down-regulation of major histocompatibility complex class I-related chain A (MICA) on tumor cells by IFNγ-induced microRNA. Journal of Immunology 2009; 182 (1): 39-43.
  5. Buchau, A., Morizane, S., Trowbridge, J., Schauber, J., Kotol, P., Bui, J.D., and Gallo, R.L. The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. Journal of Immunology 2010; 184(1):369-78.
  6. Zhang, H., Hardamon, C., Sagoe, B., Ngolab, J., Bui, J.D. Studies of the H60a locus in C57BL/6 and 129/Sv mouse strains identify the H60a 3’UTR as a regulator of H60a expression. Mol Immunol 2011; 48(4):539-45.
  7. Yadav, D., Ngolab, J., Dang, N., Bui, J.D. Studies on the antigenicity of the NKG2D ligand H60a in tumour cells. Immunology 2011; 133(2):197-205.
  8. O'Sullivan, T., Dunn, G.P., Lacoursiere, D.Y., Schreiber, R.D., and Bui, J.D.  Cancer immunoediting of the NK group 2D ligand H60a.  Journal of Immunology 2011; 187(7):3538-40.
  9. O'Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C.M., Arthur, C., White, J.M., Uppaluri, R., Andrews, D.M., Ngiow, S.F., Teng, M.W., Smyth, M.J., Schreiber, R.D., and Bui, J.D.  Cancer immunoediting by the innate immune system in the absence of adaptive immunity.  Journal of Experimental Medicine 2012; 209(10):1869-82.
  10. O'Sullivan, T., Saddawi-Konefka, R., Gross, E., Tran, M., Mayfield, S.P., Ikeda, H., and Bui, J.D.  Interleukin-17D mediates tumor rejection through recruitment of natural killer cells.  Cell Reports 2014; 7(4):989-98.